Described is an engineered viral particle programmed with T cell targeting specificity. The viral particles comprise: at least one viral vector, such as bacteriophage T4; and at least one CD4-binding protein displayed on the surface of the viral vector. Also described is a method of reactivate latent HIV-1 and cure patient with HIV-1 infection, using such an engineered viral particle.

The disclosure provides compositions and methods for producing natural products in microorganisms that are otherwise unexpressed, poorly expressed or poorly transcribed. In particular aspects, the disclosure provides compositions and methods for activating a silent gene or gene cluster with a bacteriophage and/or Streptomyces Antibiotic Regulatory Protein (SARP) transcription factor.

The present invention relates to phage T5 capsids that are devoid of genomic DNA from the phage and exposing, on their surface, at least one fusion protein of interest. The invention relates in particular to a phage T5 capsid that is deprived of genomic DNA from the phage and on its surface exposes at least one fusion protein, the fusion protein comprising: —at least one peptide fragment or protein fragment with at least 80% identity with a fragment of a decoration protein ph10; and —at least one functional fragment of an antigen, or at least one functional fragment of a toxin, or at least one receptor fragment, or at least one functional fragment of an addressing or targeting or transportation signal, or at least one functional fragment of an enzyme, or at least one functional fragment of a hormone, or at least one functional fragment of an antibody, or at least one antigen, or at least one toxin, or at least one receptor, or at least one addressing or targeting or transportation signal, or at least one enzyme, or at least one hormone, or at least one antibody, or any combination of these. The present invention also relates to methods for producing such a capsid and to vectors that enable the production thereof. The invention further relates to the fusion proteins of interest that are exposed on the capsid and to the nucleic acids encoding them. The invention also relates to nanoparticles comprising such functionalized capsids, pharmaceutical compositions comprising such nanoparticles and/or such functionalized capsids, and to therapeutic uses thereof, particularly as a medication and/or vaccine.

The present invention provides viral-based nanoparticles for therapeutic and diagnostic use, and methods for making and using the nanoparticles. Specifically, such nanoparticles comprise decoration-competent viral particles shells such as expanded capsids of phages, stabilized with engineered decoration proteins that have been linked to one or more compounds not naturally occurring on a wild type viral capsid.

The present disclosure provides compositions and methods for introducing or enhancing Aca activity in prokaryotic cells. The provided compositions and methods can be used to inhibit Acr activity in prokaryotic cells, thereby enhancing endogenous or exogenous CRISPR-Cas activity. Cells, polynucleotides, plasmids, phage, and other elements for practicing the present methods are also provided.

The present invention provides viral-based nanoparticles for therapeutic and diagnostic use, and methods for making and using the nanoparticles. Specifically, such nanoparticles comprise decoration-competent viral particles shells such as expanded capsids of phages, stabilized with engineered decoration proteins that have been linked to one or more compounds not naturally occurring on a wild type viral capsid.

The disclosure provides compositions and methods for producing natural products in microorganisms that are otherwise unexpressed, poorly expressed or poorly transcribed. In particular aspects, the disclosure provides compositions and methods for activating a silent gene or gene cluster with a bacteriophage and/or Streptomyces Antibiotic Regulatory Protein (SARP) transcription factor.

The disclosure provides compositions and methods for producing natural products in microorganisms that are otherwise unexpressed, poorly expressed or poorly transcribed. In particular aspects, the disclosure provides compositions and methods for activating a silent gene or gene cluster with a bacteriophage and/or Streptomyces Antibiotic Regulatory Protein (SARP) transcription factor.

The present invention provides viral-based nanoparticles for therapeutic and diagnostic use, and methods for making and using the nanoparticles. Specifically, such nanoparticles comprise decoration-competent viral particles shells such as expanded capsids of phages, stabilized with engineered decoration proteins that have been linked to one or more compounds not naturally occurring on a wild type viral capsid.

The present disclosure provides systems for modulating drug metabolism, specifically in the gut microbiome, by modifying target cell/s and/or population of cells comprising the target cell/s. The disclosed systems comprise the following components: (a) at least one drug metabolism modulating component comprising at least one nucleic acid sequence encoding and/or modulating at least one element participating in metabolism of at least one drug, at least one cas gene and at least one Clustered. Regularly Interspaced Short Palindromic Repeat (CRISPR) array; and (b) at least one selective component comprising at least one protospacer. The at least one protospacer is targeted by at least one spacer of the CRISPR array of (a), thereby inactivating said selective component. The present disclosure further provides, compositions and methods using the disclosed systems and any components thereof in modulation of drug metabolism and in therapeutic applications.